Work

Cytomegalovirus Infection Among Cord Blood Allogeneic Transplantation Recipients: Low Incidence of Cytomegalovirus Events without High-Dose Valacyclovir Prophylaxis

Year: 2018

Type: letter

Abstract: We read with great interest the report by Dr. Hill and colleagues entitled “A Modified Intensive Strategy to Prevent Cytomegalovirus Disease in Seropositive Umbilical Cord Blood Transplant Recipients” [1]. High-dose (6 g/day) valacyclovir prophylaxis has not been part of the umbilical cord blood transplantation (UCBT) protocol at our institution, yet we have not observed the rates of cytomegalovirus (CMV) reactivation and disease in our population that prompted the author's “intense” approach to CMV prophylaxis described [1,2].

Source: Transplantation and Cellular Therapy

DOI: 10.1016/j.bbmt.2018.06.029

Authors: Bettina M. Knoll, Driele Peixoto, Sophia Koo, Sarah P. Hammond, Vincent T. Ho, Joseph H. Antin, Robert J. Soiffer, Corey Cutler, Francisco M. Marty

Institutions: Westchester Medical Center, Brigham and Women's Hospital, Harvard University, Dana-Farber Cancer Institute, Dana-Farber Brigham Cancer Center

Language: English

Topic: Cytomegalovirus and herpesvirus research

Subfield: Epidemiology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $3,650

OpenAlex ID: W2811407223

Cites: 4

Cited by: 3

Related to: 10